CAM
BCRX icon

ClariVest Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

ClariVest Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-60,000
Closed -$611K – 743
2021
Q1 		$611K Buy
60,000
+3,400
+6% +$35.1K 0.02% 382
2020
Q4 		$422K Sell
56,600
-19,000
-25% -$97.9K 0.01% 410
2020
Q3 		$260K Sell
75,600
-4,600
-6% -$19.7K 0.01% 432
2020
Q2 		$382K Sell
80,200
-4,500
-5% -$18K 0.01% 446
2020
Q1 		$169K Buy
+84,700
New +$233K 0.01% 493
2019
Q3 		– Sell
-150,998
Closed -$572K – 668
2019
Q2 		$572K Sell
150,998
-83,900
-36% -$505K 0.01% 355
2019
Q1 		$1.91M Buy
234,898
+3,700
+2% +$31.7K 0.04% 319
2018
Q4 		$1.87M Sell
231,198
-10,800
-4% -$84K 0.04% 323
2018
Q3 		$1.85M Sell
241,998
-6,200
-2% -$41.6K 0.03% 334
2018
Q2 		$1.42M Sell
248,198
-46,968
-16% -$259K 0.02% 392
2018
Q1 		$1.41M Buy
295,166
+17,599
+6% +$90.4K 0.02% 380
2017
Q4 		$1.36M Buy
277,567
+202,867
+272% +$983K 0.02% 386
2017
Q3 		$392K Buy
+74,700
New +$383K 0.01% 405
2014
Q4 		– Sell
-15,000
Closed -$147K – 553
2014
Q3 		$147K Buy
+15,000
New +$184K 0.01% 410
2013
Q4 		– Sell
-9,900
Closed -$72K – 597
2013
Q3 		$72K Buy
+9,900
New +$50.2K ﹤0.01% 426

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ClariVest Asset Management's BCRX Position: Q2 2021 in Review

ClariVest Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 60,000 shares — an estimated $611K sold.

ClariVest Asset Management first reported a position in BCRX in Q3 2013 and held it in 15 quarters. The position peaked at $1.91M in Q1 2019. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

  • ClariVest Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 60,000 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $611K.
  • ClariVest Asset Management first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 15 quarters.
  • ClariVest Asset Management's BioCryst Pharmaceuticals position peaked at $1.91M in Q1 2019.
  • 195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on ClariVest Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.